X

Trial Profile

A Multi-Centre, Open Label, Two Arm Randomized, Phase 2 Trial to Study the Efficacy and Safety of Itolizumab in COVID-19 Complications

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 02 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Itolizumab (Primary) ; Antibacterials; Antivirals; Hydroxychloroquine
Indications Adult respiratory distress syndrome; COVID 2019 infections; Cytokine release syndrome
Focus Registrational; Therapeutic Use
Sponsors Biocon

Most Recent Events

29 Apr 2021 According to a Biocon media release, results from this trial were published in the Expert Opinion on Biological Therapy Journal.
17 Jul 2020 New trial record
13 Jul 2020 Based on the results of this study, company is planning to conduct a global randomized controlled clinical trial of itolizumab in COVID-19 patients (CTP700325091).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com